Media stories about Derma Sciences (NASDAQ:DSCI) have trended somewhat positive recently, AlphaOne Sentiment Analysis reports. AlphaOne, a unit of Accern, scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Derma Sciences earned a news impact score of 0.06 on AlphaOne’s scale. AlphaOne also gave headlines about the medical instruments supplier an impact score of 43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Derma Sciences (NASDAQ:DSCI) remained flat at $7.00 during trading on Thursday. The firm’s 50 day moving average price is $6.82 and its 200-day moving average price is $5.28. Derma Sciences has a one year low of $2.92 and a one year high of $7.05.

Several research firms have recently weighed in on DSCI. Roth Capital downgraded shares of Derma Sciences from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 18th. Zacks Investment Research raised shares of Derma Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, January 10th.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

5 Day Chart for NASDAQ:DSCI

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with's FREE daily email newsletter.